Cargando…

Is adjuvant immunotherapy a new standard for non‐pathological complete response patients with resectable esophageal squamous cell carcinoma?

Detalles Bibliográficos
Autores principales:	Wang, Jun, Hui, Zhouguang, Pang, Qingsong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley & Sons Australia, Ltd 2022
Materias:	Letters to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9626336/ https://www.ncbi.nlm.nih.gov/pubmed/36214057 http://dx.doi.org/10.1111/1759-7714.14641

Ejemplares similares

Reply: Bayesian analysis supports the role of neoadjuvant chemoradiation followed by surgery for resectable locoregional esophageal cancer
por: Bao, Yongxing, et al.
Publicado: (2022)

Adjuvant immunotherapy in resected esophageal squamous cell carcinoma: a gospel to the non-pCRs
por: Zhang, Zhihui, et al.
Publicado: (2021)

Adjuvant chemotherapy or immunotherapy for completely resected stage IB non-small cell lung cancer: still a grey zone?
por: Lee, Kuan-Yu, et al.
Publicado: (2023)

Survival of Neoadjuvant and Adjuvant Therapy Compared With Surgery Alone for Resectable Esophageal Squamous Cell Carcinoma: A Systemic Review and Network Meta-Analysis
por: Ma, Zeliang, et al.
Publicado: (2021)

Immunotherapy for Esophageal Squamous Cell Carcinoma
por: Kojima, Takashi, et al.
Publicado: (2017)

Efficacy of intensity-modulated radiotherapy for resected thoracic esophageal squamous cell carcinoma
por: Zhang, Wencheng, et al.
Publicado: (2015)

Effect of Adjuvant Radiation Dose on Survival in Patients with Esophageal Squamous Cell Carcinoma
por: Han, Weiming, et al.
Publicado: (2022)

Neoadjuvant immunotherapy for resectable esophagal squamous cell carcinoma: An ace up the sleeve
por: Zhou, Qing, et al.
Publicado: (2023)

Adjuvant therapy in patients with rectal adenocarcinoma treated with neoadjuvant chemoradiotherapy and radical resection in pathological stages I–III
por: Lino-Silva, Leonardo S., et al.
Publicado: (2020)

Immunotherapy with or without radiotherapy for metastatic or recurrent esophageal squamous cell carcinoma: A real-world study
por: Wu, Xiaoyue, et al.
Publicado: (2022)

A Novel Predictor of Pathologic Complete Response for Neoadjuvant Immunochemotherapy in Resectable Locally Advanced Esophageal Squamous Cell Carcinoma
por: Yang, Yalan, et al.
Publicado: (2023)

Adjuvant Therapy for a Microscopically Incomplete Resection Margin after an Esophagectomy for Esophageal Squamous Cell Carcinoma
por: Qiu, Bo, et al.
Publicado: (2017)

Adjuvant Therapy for Esophageal Squamous Cell Carcinoma
por: Sun, Jong-Mu
Publicado: (2020)

Neoadjuvant versus adjuvant treatment: which one is better for resectable esophageal squamous cell carcinoma?
por: Xu, Yaping, et al.
Publicado: (2012)

Simultaneous videothoracoscopic resection for thymoma and lung squamous cell carcinoma, and review of the literature
por: Sayan, Muhammet, et al.
Publicado: (2022)

Predictors of pathological complete response to neoadjuvant chemoradiotherapy for esophageal squamous cell carcinoma
por: Huang, Ren-Wen, et al.
Publicado: (2014)

Upfront surgery and pathological stage-based adjuvant chemoradiation strategy in locally advanced esophageal squamous cell carcinoma
por: Chen, Hui-Shan, et al.
Publicado: (2018)

Efficacy and safety of neoadjuvant chemotherapy and immunotherapy in locally resectable advanced esophageal squamous cell carcinoma
por: Wu, Zhigang, et al.
Publicado: (2021)

Immune checkpoint inhibitors for esophageal squamous cell carcinoma: a narrative review
por: Zhang, Wencheng, et al.
Publicado: (2020)

Optimal Adjuvant Treatment for Curatively Resected Thoracic Esophageal Squamous Cell Carcinoma: A Radiotherapy Perspective
por: Kim, Kyung Hwan, et al.
Publicado: (2017)

Failure patterns after adjuvant chemoradiotherapy following endoscopic resection for superficial esophageal squamous cell carcinoma
por: Ikawa, Toshiki, et al.
Publicado: (2019)

Pathologic Complete Response Prediction to Neoadjuvant Immunotherapy Combined with Chemotherapy in Resectable Locally Advanced Esophageal Squamous Cell Carcinoma: Real-World Evidence from Integrative Inflammatory and Nutritional Scores
por: Feng, Jifeng, et al.
Publicado: (2022)

Clinicopathological relevance of stem cell marker growth and differentiation factor 3 in esophageal squamous cell carcinoma
por: Moghaddam, Sara Tahbazzadeh, et al.
Publicado: (2023)

Long lasting complete response with immunotherapy in a metastatic bladder carcinoma: a case report
por: Magalhães, Denise S.T., et al.
Publicado: (2021)

The Prognostic Value of TP53 Alteration in Patients with Head and Neck Squamous Cell Carcinoma Receiving Immunotherapy
por: Jiang, Chao, et al.
Publicado: (2022)

Esoxx added to standard therapy accelerates the healing of esophagitis
por: Pietrzak, Anna Maria
Publicado: (2023)

Pathological complete response after neoadjuvant treatment determines survival in esophageal squamous cell carcinoma patients (NEOCRTEC5010)
por: Shen, Jianfei, et al.
Publicado: (2021)

A serum metabolomics analysis reveals a panel of screening metabolic biomarkers for esophageal squamous cell carcinoma
por: Lv, Jiali, et al.
Publicado: (2021)

Tumor‐infiltrating CD8(+) T cell is prognostic and predicts adjuvant chemotherapy benefit in patients with limited‐stage small cell esophageal carcinoma
por: Zhang, Zhihui, et al.
Publicado: (2021)

Impact of adjuvant chemotherapy for radically resected esophageal squamous cell carcinoma: a propensity score matching analysis
por: Chen, Shao-bin, et al.
Publicado: (2023)

Regarding “Neoadjuvant Versus Adjuvant Chemotherapy for Resectable Metastatic Colon Cancer in Non-academic and Academic Programs”
por: Su, I-Hsuan, et al.
Publicado: (2023)

Flow Cytometry: A Rapid and Robust Adjuvant Technique for Pathological Diagnosis
por: Jain, Monica, et al.
Publicado: (2012)

Comment on “Prognosis of Patients With Esophageal Carcinoma Following Routine Thoracic Duct Resection: A Propensity-Matched Analysis of 12,237 Patients Based on the Comprehensive Registry of Esophageal Cancer in Japan”
por: Udagawa, Harushi
Publicado: (2023)

PMN‐MDSCs‐induced accumulation of CD8+CD39+ T cells predicts the efficacy of chemotherapy in esophageal squamous cell carcinoma
por: Qin, Guohui, et al.
Publicado: (2020)

Expression of AKR1C3, β-Catenin and LEF1 in Esophageal Squamous Cell Carcinoma and the Relationship with Radiation Resistance
por: Xiong, Wei, et al.
Publicado: (2021)

Prognostic value of occult lymph node metastases in patients with completely resected esophageal squamous cell carcinoma
por: Chen, Shao-bin, et al.
Publicado: (2020)

In Reply: Overall Survival of Resectable Metastatic Colon Cancer Treated With Neoadjuvant Chemotherapy or Adjuvant Chemotherapy in Non-academic Program
por: Hao, Zhonglin, et al.
Publicado: (2023)

Phosphoproteomics reveals therapeutic targets of esophageal squamous cell carcinoma
por: Li, Yi, et al.
Publicado: (2021)

Perioperative immunotherapy for esophageal squamous cell carcinoma: Now and future
por: Liu, Yong
Publicado: (2023)

Role of adjuvant treatment in stage IB non-small cell lung carcinoma
por: Park, Cheol-Kyu, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_qin25lrnq7q2c50lhb40a9iqir